TAIPEI, March 5, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. ("TWi") today announced that its Board of Directors has unanimously approved to appoint Ms. Tina Guilder as its new President & Chief Executive Officer (CEO) who will continue to be the President of its wholly-owned subsidiary, TWi Pharmaceuticals USA. TWi's current President, Dr. Calvin Chen, will become the Special Advisor to Ms. Guilder and remain as the President of TWi Biotechnology, Inc. The appointment of Ms. Guilder will be effective April 1, 2015. The Board has also decided to appoint Ms. Eva Ho as TWi's Chief Financial Officer (CFO), effective March 9, 2015.
Since its inception, TWi has been focusing on high-barrier specialty generics, which are targeted for the U.S. market. This core strategy was further emphasized by the establishment of its wholly-owned U.S. subsidiary in 2014, which will sell and distribute products in TWi label directly in the U.S. market. At the eve of its upcoming official product launch, the Board has decided to strengthen TWi's implementation of its business strategy with Ms. Guilder's practical experience of managing commercial operations at Teva, the world's premier generic pharmaceutical company, to transform TWi into a leading specialty generic pharmaceutical company and successfully commercialize its products in the U.S., the world's largest pharmaceutical market.
Ms. Guilder has an MBA degree from the University of Southern California. Prior to joining TWi, she was the Vice President of Business Development & Alliance Management of Teva Pharmaceuticals USA. Ms. Guilder brings TWi over 18 years of experience in the pharmaceutical / healthcare industry with emphasis on finance as well as corporate and business development efforts for generics, specialty brand, and biosimilars segments, which included identifying and negotiating opportunities in M&A, joint ventures, divestitures, technology/product in/out-license, and alliances for both brand and generic businesses across the Americas. One of her key accomplishments at Teva was leading the commercial assessment, valuation / due diligence activities for acquisitions and divestitures.
Ms. Ho is a Certified Public Accountant (CPA) in the U.S. She served as the CFO at Acer and Testrite Group, both publicly listed companies in Taiwan, and also held financial leadership positions in Sun Microsystems and Oracle Taiwan. She brings to TWi over 25 years of corporate finance and administration experience, and most of which were in large conglomerates.
Dr. Chih-Ming Chen, Chairman of TWi Pharmaceuticals, Inc. (TWi), commented, "we are excited of the Board's appointment of Ms. Tina Guilder as the new President & CEO of TWi. With Ms. Guilder's extensive operational experience in the US generics market along with her expansive knowledge in market intelligence, regulatory affairs, and commercialization, she is the ideal leader to transform TWi into a world-class specialty generic pharmaceutical company. In addition, we are thrilled to see the Board's approval in the appointment of Ms. Eva Ho as TWi's CFO. With her years of experience in the finance and accounting arena, we are confident that she can support the CEO in achieving TWi's commercialization goals. At the same time, we appreciate Calvin's achievement and contribution during the past few years in taking TWi from a private R&D company into one of the most well-respected publicly-traded companies in Taiwan."
About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.
Tel: +886-2-2657-3350 #407
email: [email protected]
SOURCE TWi Pharmaceuticals, Inc.